EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of stage III or metastatic NSCLC without EGFR sensitizing mutation or ALK translocation * Age ≥ 22 years * Have a PD-L1 positive (TPS≥1%) tumor by local laboratory assessment * Have evaluable (measureable or non-measureable) disease in thorax per RECIST 1.1 * ECOG performance status of 0 to 1 * Have not received prior treatments for metastatic or current advanced NSCLC. Palliative treatment is allowed and subjects who received adjuvant, neoadjuvant chemotherapy or chemoradiotherapy with curative intent for non-metastatic disease are eligible if therapy completed at least 12 months prior to the development of metastatic or current advanced disease. * Life expectancy of at least 3 months * Able to operate the NovoTTF-200T device Exclusion Criteria: * Has known active or untreated CNS metastases and/or carcinomatous meningitis * Has an EGFR sensitizing mutation and/ or ALK translocation * Can be treated with curative intent with either surgical resection and/or chemoradiation * Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or an agent directed to another stimulatory or co-inhibitory T cell receptor within the past 12 months * Has received prior systemic anti-cancer therapy for metastatic or current advanced NSCLC (palliative radiotherapy is allowed) * Being unable to operate the NovoTTF-200T device independently or with the help of a caregiver * Pregnancy or breastfeeding * Received live vaccine in the past 30 days or had major surgery in the last 3 weeks * Is expected to require any other form of systemic or localized antineoplastic therapy while on study